Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE +0.17%, DAX +0.26%, CAC40 +0.61%

Apr 25 ,2025

  • Synopsis

    • European indices are set to open higher today with Asian equities advancing. Tech/semis driving strength in Hong Kong, Korea, Japan and Taiwan. S&P 500 futures extending gains. US equities were higher in Thursday trading, near best levels.

    • Trump said on Wednesday after the close he may call Fed Chair Powell to push for rate cuts. Argued that he believes Powell is making a mistake by not cutting rates but hopeful he will do the right thing and ease policy

    • In central banks, Bank of Russia's key rate meeting, medium-term economic forecast at 11:30BST followed by press conf. by the governor at 13:00BST. The bank is expected to keep its benchmark interest rate unchanged at 21%. SNB's Steiner and Schlegel speak at the bank's general meeting of shareholders. Riksbank's Breman will discuss at 12:00CET current monetary policy at event hosted by ABG Sundal Collier. Bundesbank's Lienenkämper panellist at 13:00CET at event hosted by Leibniz-Institut SAFE

    • Macroeconomic releases due today include: UK Mar retail sales, France April business confidence

    • In corporate news: Q1 earnings reports from Stora Enso, Saab, Heijmans, Palfinger, ATOSS Software, Nordex, Safran, Holcim, Duni.

  • Politics/Macro/World News

    • ECB Sees Inflation Job Almost Done Despite Tariff Mess (Bloomberg )

    • Exclusive: Trump poised to offer Saudi Arabia over $100 billion arms package, sources say (Reuters )

    • Starmer challenges Trump peace plan for Ukraine (Telegraph )

  • Top company news

    • Earnings/updates

      • SAF.FP (Safran) -- reports Q1 revenue €7.38B vs consensus €7.05B; confirms FY25 outlook excluding any potential impact of tariffs

      • HOLN.SW (Holcim) -- reports Q1 recurring EBIT CHF515M vs StreetAccount CHF497.4M

      • AC.FP (Accor) -- reports Q1 revenue €1.35B vs StreetAccount €1.31B; reaffirms mid-term growth outlook

      • ML.FP (Cie Generale des Etablissements Michelin SA) -- reports Q1 revenue €6.52B vs consensus €6.43B

      • SGO.FP (Compagnie de Saint-Gobain) -- reports Q1 revenue €11.72B vs StreetAccount €11.56B; reaffirms FY operating margin guidance

      • DG.FP (VINCI SA) -- reports Q1 revenue €16.32B vs StreetAccount €16.34B; reaffirms 2025 guidance

      • GNFT.FP (GENFIT) -- reports FY net income €1.5M vs FactSet €7.0M [5 est, (€16.2)-34.9M]

      • CA.FP (Carrefour) -- reports Q1 sales inc. VAT (pre-IAS 29) €22.65B vs StreetAccount €22.72B

      • UMI.BB (Umicore) -- recorded solid Q1 performance, reaffirms 2025 adj. EBITDA guidance

      • URW.FP (Unibail-Rodamco-Westfield) -- reports Q1 Proportionate revenue €943.3M vs year-ago €942.8M; confirms FY profit guidance

      • LIGHT.NA (Signify) -- reports Q1 net income €67M vs consensus €49M

      • IMCD.NA (IMCD) -- reports Q1 Operating EBITA €142M vs StreetAccount €141.8M; says impossible to give a reliable near-term trading outlook

      • ADP.FP (Aeroport de Paris) -- reports Q1 revenue €1.49B vs FactSet €1.42B [4 est, €1.40-1.44B]

      • SPIE.FP (SPIE) -- reports Q1 revenue €2.42B vs FactSet €2.45B [2 est, €2.42-2.48B]; reaffirms FY guidance

      • SK.FP (SEB) -- reports Q1 revenue €1.91B vs FactSet €1.93B [2 est, €1.91-1.94B]

      • ATE.FP (Alten) -- reports Q1 revenue €1.06B vs FactSet €1.07B [1 est]

      • PHM.SM (Pharma Mar) -- reports Q1 net income (€3.9M) vs FactSet €4.1M [2 est, (€4)-12.2M]

      • MF.FP (Wendel) -- Q1 Trading Update: reports NAV as of 31-Mar of €176.7/share

      • WDP.BB (Warehouses de Pauw) -- reports Q1 EPRA EPS €0.36 vs FactSet €0.36 [1 est]; reaffirms FY guidance

      • CLARI.FP (Clariane) -- preannounces Q1 revenue €1.32B vs year-ago €1.31B; occupancy rate of nursing homes was 90.4% vs. 89.6% year-ago

      • LSS.FP (Lectra) -- reports Q1 net income €5.8M vs FactSet €10.3M [2 est, €9.7-10.8M]

      • 4FZ.GR (Orbia Advance Corp SAB de CV) -- Orbia Advance Corp SAB de CV reports Q1 net majority income ($54M) vs year-ago ($74M)

      • FII.FP (Lisi) -- reports Q1 revenue €486.7M, +8% vs year-ago €449.3M

      • BHG.SS (Lightshop) -- reports Q1 EPS SEK0.27 vs FactSet SEK0.06 [3 est, SEK0.01-0.12]

      • BOOZT.SS (Boozt Fashion) -- reports Q1 adjusted EPS SEK0.44 vs FactSet SEK0.21 [4 est, (SEK0.10)-0.33]

      • BOOZT.SS (Boozt Fashion) -- Follow-up: Boozt Fashion reports Q1 results

      • NXI.FP (Nexity) -- reports Q1 revenue €590M vs FactSet €498.0M [1 est]

      • CGM.FP (Cegedim) -- reports preliminary H1 revenue €161.3M vs year-ago €155.9M

      • GBT.FP (Guerbet) -- reports H1 revenue €180.1M, (8%) vs year-ago €194.3M

      • MTU.FP (Manitou BF) -- reports Q1 revenue €600M, (12%) vs year-ago €685M

      • MRN.FP (Mersen) -- reports Q1 revenue €304.9M, (2%) vs year-ago €312.5M

      • TKO.FP (Tikehau Capital) -- reports Q1 Group AUM as of 31-Mar of €50.6B, +14% y/y

      • SCHP.FP (Seche Environnement) -- reports Q1 revenue €280.3M vs FactSet €279.0M [1 est]

    • M&A

      • SWTX (Springworks Therapeutics) -- reportedly close to agreement to be acquired by Merck KGaA for ~$47 per share -- media report

      • MRK.GR (Merck KGaA) -- confirms late-stage discussions with SpringWorks Therapeutics on potential acquisition at basis price of ~$47 per share

      • BBVA.SM (Banco Bilbao Vizcaya Argentaria) -- Spain's CMMC expected to approve BBVA's proposed acquisition of Banco de Sabadell as soon as next week with concessions -- Reuters, citing sources

      • BAMI.IM (Banco BPM) -- EU sets a provisional deadline of 4-Jun to rule on UniCredit's acquisition of Banco BPM

      • RECSI.NO (REC Silicon) -- announces the agreement for an all cash offer by Anchor AS to acquire all outstanding shares at NOK 2.20/sh (NOK 925M)

    • Healthcare

      • PFE (Pfizer) -- FDA approves sNDA for Ibrance, adding PFS data from INAVO120 trial to the label

      • ROG.SW (Roche Holding) -- Roche publishes in the New England Journal of Medicine phase III data showing single-dose Xofluza significantly reduces influenza virus transmission

      • IVA.FP (Inventiva) -- announces publication in Clinical Gastroenterology and Hepatology

      • PHXM.FP (Phaxiam Therapeutics) -- provides update on the receivership procedure

      • TNG.FP (Transgene) -- Q1 Business Update: Over Q1 of 2025, all of Transgene's preclinical and clinical assets progressed in line with expectations

      • VVY.NA (Vivoryon Therapeutics) -- enters into a Standby Equity Purchase agreement of up to €15M, with Yorkville Advisors Global, LP

    • Other

      • GOGL.NO (Golden Ocean Group) -- SEC filing: SCHEDULE 13D/A (Filed by CMB.TECH NV)

      • CO.FP (Casino Guichard-Perrachon) -- Casino Group announces repayment to Quatrim secured bondholders

      • PUB.FP (Publicis Groupe) -- implements a program for the acquisition of its own shares, for a maximum amount of €150M.

      • INGA.NA (ING Groep) -- files automatic shelf of indeterminate amount - F-3ASR

      • INGA.NA (ING Groep) -- files mixed securities shelf of indeterminate size - F-3ASR

      • EPI.A.SS (Epiroc) -- establishes sponsored ADRs in United States

      • GALP.PL (Galp Energia SGPS) -- appoints Maria João Carioca and João Diogo Marques da Silva as co-CEOs

      • FGR.FP (Eiffage) -- wins the contract worth a total of €134M to build two solar photovoltaic power plants with 300 MWp in total capacity at Córdoba in Spain?

      • ATE.FP (Alten) -- proposes a dividend of €1.50/ordinary share for 2024

      • Ecopetrol evaluating the strategy to ensure continuity of gas projects in Southern Caribbean

      • UK March car manufacturing +17.1% y/y to 79,018 units -- SMMT

      • Unibail-Rodamco-Westfield US Malls outperform for tenant sales, MGR uplift

  • Key rating changes

    • Upgrades

      • LI.FP (Klepierre) -- to buy from hold at Berenberg

      • (RI.FP) Pernod Ricard -- to buy from hold at Kepler Cheuvreux

      • TKWY.NA (Just Eat Takeaway.com) -- to neutral from underperform at Santander

      • HSBC upgrades SHL.GR, SOON.SW

    • Downgrades

      • VRLA.FP (Verallia) -- to hold from buy at Stifel

      • HSBC downgrades ALGN, ERF.FP, IQV, and SN.LN

      • BIOT.SS (Biotage) downgraded to hold from buy at Handelsbanken

    • Initiations

      • EMMN.SW (Emmi) -- buy at Berenberg

  • Data

    • Nikkei +1.79% to 35667.93

    • Hang Seng +1.13% to 22157.14

    • Shanghai Composite +0.09% to 3300.21

    • S&P futures +22.3 vs prior close of 5511.3

    • €-$ (0.0053) or (0.47%) to 1.1337

    • $-¥ +1.06 or +0.75% to 143.69

    • €-¥ +0.45 or +0.28% to 162.89

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE